The administration of RJ over a 16-week period significantly attenuated final body weight gain, reduced the HOMA-IR index, and mitigated increases in glucose and insulin levels, while also improving dyslipidemia in the HFD-fed rats. Here, INS is linked to metabolic syndrome.